Glucophage Xr

Diabetic Ketoacidosis, Congestive Heart Failure, Type 1 Diabetes + 16 more

Treatment

22 FDA approvals

20 Active Studies for Glucophage Xr

What is Glucophage Xr

Metformin

The Generic name of this drug

Treatment Summary

Metformin is a medication used to treat type II diabetes. It works by decreasing blood sugar levels without causing hypoglycemia. Metformin also helps to reduce insulin resistance and reduces fasting insulin levels. This medication can also help with weight loss in obese people with type II diabetes. It was first approved in Canada in 1972 and in the US in 1995 and is available in regular or extended-release forms.

Metformin Hydrochloride

is the brand name

image of different drug pills on a surface

Glucophage Xr Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Metformin Hydrochloride

Metformin

2002

1263

Approved as Treatment by the FDA

Metformin, otherwise known as Metformin Hydrochloride, is approved by the FDA for 22 uses which include Cardiovascular Diseases and Kidney Failure .

Cardiovascular Diseases

Used to treat established cardiovascular disease in combination with Dapagliflozin

Kidney Failure

Used to treat End Stage Renal Disease (ESRD) in combination with Dapagliflozin

Heart Failure

Used to treat Heart Failure in combination with Dapagliflozin

Chronic Kidney Disease

Used to treat Chronic Kidney Disease (CKD) in combination with Dapagliflozin

Type 2 Diabetes Mellitus

Used to treat Type 2 Diabetes Mellitus in combination with Dapagliflozin

Ketosis

Used to treat Diabetic Ketoacidosis in combination with Saxagliptin

Type 2 Diabetes

Used to treat Type 2 Diabetes Mellitus in combination with Dapagliflozin

Diet

Used to treat Diet in combination with Dapagliflozin

Hospitalizations

Used to treat Hospitalizations in combination with Dapagliflozin

Congestive Heart Failure

Used to treat Heart Failure in combination with Dapagliflozin

Physical Activity

Used to treat Exercise in combination with Dapagliflozin

Ejection fraction decreased

Used to treat Ejection fraction decreased in combination with Dapagliflozin

Heart Failure

Used to treat NYHA Functional Class II-IV Heart Failure in combination with Dapagliflozin

Chronic Kidney Disease (CKD)

Used to treat Chronic Kidney Disease (CKD) in combination with Dapagliflozin

Type 1 Diabetes Mellitus

Used to treat Type 1 Diabetes Mellitus in combination with Sitagliptin

Diabetic Ketoacidosis

Used to treat Diabetic Ketoacidosis in combination with Saxagliptin

Cardiovascular Mortality

Used to treat Cardiovascular Mortality in combination with Dapagliflozin

Renal Insufficiency

Used to treat decreased estimated glomerular filtration rate in combination with Dapagliflozin

Diabetes Mellitus

Used to treat uncontrolled diabetes in combination with Rosiglitazone

Cardiovascular Disease

Used to treat Cardiovascular Risk in combination with Dapagliflozin

Heart failure

Used to treat Heart Failure in combination with Dapagliflozin

Type 1 Diabetes

Used to treat Type 1 Diabetes Mellitus in combination with Sitagliptin

Effectiveness

How Glucophage Xr Affects Patients

Insulin helps to keep your blood glucose levels in balance. People with type 2 diabetes have a harder time processing insulin, which can cause their blood sugar levels to be too high. Metformin helps by decreasing the amount of glucose your liver makes, slowing down how much glucose is absorbed by your body, and making it easier for insulin to work. Metformin does not cause too much insulin to be released like some other diabetes treatments do. In a study, people taking metformin for 29 weeks had their fasting plasma glucose (blood sugar levels when not eating) drop by an average of 59 mg/dL, while those taking a

How Glucophage Xr works in the body

Metformin works to lower blood sugar levels by decreasing the amount of sugar produced in the liver, reducing the amount of sugar absorbed from food, and improving the body’s sensitivity to insulin. Specifically, metformin accumulates in cells and the mitochondria, and inhibits a molecule called mitochondrial complex I. This prevents ATP production, leading to an increase in AMP:ATP ratios. This activates an enzyme called AMP-activated protein kinase (AMPK), which helps regulate glucose metabolism. Metformin also inhibits _fructose-1,6-bisphosphatase_ and adenylate cyclase

When to interrupt dosage

The portion of Glucophage Xr is dependent upon the recognized condition, including Diet, insufficient answer to metformin and Diabetic Ketoacidosis. The measure fluctuates according to the strategy of delivery (e.g. Oral or Tablet - Oral) indicated in the table beneath.

Condition

Dosage

Administration

Type 2 Diabetes

500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg

Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated, Tablet, coated - Oral, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral

Renal Insufficiency

500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg

Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated, Tablet, coated - Oral, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral

Cardiovascular Diseases

500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg

Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated, Tablet, coated - Oral, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral

Insulin Resistance

500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg

Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated, Tablet, coated - Oral, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral

inadequate response to metformin

500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg

Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated, Tablet, coated - Oral, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral

Diabetes Mellitus

500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg

Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated, Tablet, coated - Oral, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral

Congestive Heart Failure

500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg

Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated, Tablet, coated - Oral, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral

Chronic Kidney Disease

500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg

Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated, Tablet, coated - Oral, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral

Diabetic Ketoacidosis

500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg

Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated, Tablet, coated - Oral, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral

Physical Activity

500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg

Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated, Tablet, coated - Oral, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral

Kidney Failure

500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg

Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated, Tablet, coated - Oral, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral

Diet

500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg

Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated, Tablet, coated - Oral, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral

Hospitalizations

500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg

Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated, Tablet, coated - Oral, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral

Heart Failure

500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg

Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated, Tablet, coated - Oral, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral

Type 1 Diabetes

500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg

Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated, Tablet, coated - Oral, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral

Polycystic Ovarian Syndrome

500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg

Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated, Tablet, coated - Oral, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral

Cardiovascular Disease

500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg

Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated, Tablet, coated - Oral, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral

Cardiovascular Mortality

500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg

Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated, Tablet, coated - Oral, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral

Ejection fraction decreased

500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg

Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated, Tablet, coated - Oral, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral

Warnings

Glucophage Xr has twenty contraindications, hence it should not be consumed for the situations indicated in the following table.

Glucophage Xr Contraindications

Condition

Risk Level

Notes

Liver Failure

Do Not Combine

Renal Insufficiency

Do Not Combine

Heart Arrest

Do Not Combine

Diabetic Ketoacidosis

Do Not Combine

Operative Surgery

Do Not Combine

Metabolic acidosis

Do Not Combine

Heart Failure

Do Not Combine

Renal Insufficiency

Do Not Combine

kidney function unknown

Do Not Combine

Hypovolemic Shock

Do Not Combine

serum creatinine above upper limit for age range

Do Not Combine

ethanol

Do Not Combine

Acute Coryza

Do Not Combine

Hypoxemia

Do Not Combine

Liver Failure

Do Not Combine

Acidosis, Lactic

Do Not Combine

Diabetic Ketoacidosis

Do Not Combine

Renal Insufficiency

Do Not Combine

Renal Insufficiency, Chronic

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Metformin may interact with Pulse Frequency

There are 20 known major drug interactions with Glucophage Xr.

Common Glucophage Xr Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The excretion of Abemaciclib can be decreased when combined with Metformin.

Procainamide

Major

The excretion of Procainamide can be decreased when combined with Metformin.

Topotecan

Major

The excretion of Topotecan can be decreased when combined with Metformin.

Abacavir

Minor

Metformin may decrease the excretion rate of Abacavir which could result in a higher serum level.

Aclidinium

Minor

Metformin may decrease the excretion rate of Aclidinium which could result in a higher serum level.

Glucophage Xr Toxicity & Overdose Risk

The toxic dose of metformin in rats is 1g/kg when taken orally, 500mg/kg when taken intraperitoneally, and 300mg/kg when taken subcutaneously. The toxic dose in mice is 1450 mg/kg when taken orally, 420 mg/kg when taken intraperitoneally, and 225 mg/kg when taken subcutaneously. Taking too much metformin may increase the risk of lactic acidosis, which is characterized by high blood lactate levels, anion gap acidosis, and an increased lactate:pyruvate ratio. Risk factors for l

image of a doctor in a lab doing drug, clinical research

Glucophage Xr Novel Uses: Which Conditions Have a Clinical Trial Featuring Glucophage Xr?

Currently, there are 346 active studies investigating the capacity of Glucophage XR to treat Type 2 Diabetes, Type 1 Diabetes, and lack of response to metformin.

Condition

Clinical Trials

Trial Phases

Congestive Heart Failure

181 Actively Recruiting

Not Applicable, Phase 1, Early Phase 1, Phase 2, Phase 3, Phase 4

Type 1 Diabetes

128 Actively Recruiting

Not Applicable, Phase 3, Phase 2, Early Phase 1, Phase 1, Phase 4

Chronic Kidney Disease

96 Actively Recruiting

Phase 1, Phase 2, Not Applicable, Phase 3, Phase 4, Early Phase 1

Cardiovascular Diseases

0 Actively Recruiting

Cardiovascular Disease

31 Actively Recruiting

Not Applicable, Phase 3, Phase 2

Type 2 Diabetes

184 Actively Recruiting

Not Applicable, Phase 2, Phase 4, Phase 1, Early Phase 1, Phase 3

Kidney Failure

38 Actively Recruiting

Phase 4, Phase 2, Phase 3, Not Applicable, Phase 1

Physical Activity

30 Actively Recruiting

Not Applicable, Phase 2

Insulin Resistance

1 Actively Recruiting

Not Applicable

Renal Insufficiency

0 Actively Recruiting

Cardiovascular Mortality

0 Actively Recruiting

Ejection fraction decreased

0 Actively Recruiting

Hospitalizations

2 Actively Recruiting

Not Applicable

Diabetic Ketoacidosis

2 Actively Recruiting

Phase 1, Phase 2

Polycystic Ovarian Syndrome

9 Actively Recruiting

Phase 1, Not Applicable

inadequate response to metformin

0 Actively Recruiting

Heart Failure

0 Actively Recruiting

Diet

5 Actively Recruiting

Not Applicable, Phase 1

Diabetes Mellitus

0 Actively Recruiting

Glucophage Xr Reviews: What are patients saying about Glucophage Xr?

5

Patient Review

8/28/2010

Glucophage Xr for Type 2 Diabetes Mellitus

I have been taking the generic form for months and have suffered diarrhea to the point that I'm leary of going out. It strikes fast and furious. I have been recently switched to Glucophage XR 500mg 2 2 times daily and it has calmed down. Problem, insurance won't pay for it and it's too expensive to buy.

5

Patient Review

9/13/2010

Glucophage Xr for Type 2 Diabetes Mellitus

I found this medication very easy to use and it gave me good control over my blood sugar levels.

5

Patient Review

6/13/2012

Glucophage Xr for Type 2 Diabetes Mellitus

This medication didn't have a huge impact on my blood sugar, but I did notice that while I was taking a break from it (for a CAT scan), my urinary incontinence disappeared. My doctor and I decided that it wasn't worth the tradeoff, so I stopped taking the drug and am now focusing on diet instead. So far, so good!

5

Patient Review

5/4/2010

Glucophage Xr for Type 2 Diabetes Mellitus

This medication sometimes gives me diarrhea, but I've also found that it increases my sex drive. I would recommend reading the leaflet from the pharmacy before starting this medication, as it contains a lot of useful information.

4.7

Patient Review

6/27/2010

Glucophage Xr for Type 2 Diabetes Mellitus

I've been on this medication for about a week. Unfortunately, I often wake up in the middle of the night to vomit and/or have diarrhea. I'm not sure if the cure is worse than the disease at this point.

4.7

Patient Review

1/18/2015

Glucophage Xr for Type 2 Diabetes Mellitus

I've been finding these tablets in my stool for a few months now. They don't seem to be digesting properly in my stomach. I'm also on insulin with the Glucophage. My doctor prescribed it like this. I've been diabetic type 1 for 16 years. Should I stop taking them? I did for 2 days and felt that my sugar levels stayed high.

4

Patient Review

11/24/2010

Glucophage Xr for Type 2 Diabetes Mellitus

This medication caused me to have lots of loose bowels.

4

Patient Review

3/4/2009

Glucophage Xr for Type 2 Diabetes Mellitus

3.3

Patient Review

9/28/2016

Glucophage Xr for Prevention of Type 2 Diabetes Mellitus

I've been taking 500mg of this medication for eight months and have experienced several negative side effects, including bloating, loss of appetite, constipation, and weight loss.

3.3

Patient Review

1/7/2011

Glucophage Xr for Prevention of Type 2 Diabetes Mellitus

After taking my 1500mg dose of this medication, I had a bowel movement and found two orange tablets in my stool. These were the size of the glucophage pills. Should I discontinue the medication? My fasting blood sugar is no higher than 118 and my HgbA1C is 5.4%.

3

Patient Review

11/2/2009

Glucophage Xr for Type 2 Diabetes Mellitus

2.7

Patient Review

10/26/2010

Glucophage Xr for Type 2 Diabetes Mellitus

Sometimes I experience severe diarrhea, but since combining this medication with diamicron, I have been doing much better.

2.7

Patient Review

8/15/2011

Glucophage Xr for Prevention of Type 2 Diabetes Mellitus

I got severe diarrhea.

2.7

Patient Review

8/5/2011

Glucophage Xr for Type 2 Diabetes Mellitus

So far, so good.

2.3

Patient Review

9/23/2013

Glucophage Xr for Type 2 Diabetes Mellitus

I was hesitant to go on medication, but after a year of trying to control my blood sugar with diet alone and seeing little results, I decided to give it a try. I started taking 2000mg of Metformin XR daily, in two 500mg doses with breakfast and dinner. The results were remarkable – my blood sugar has been consistently between 100 and 125, and I've been able to add back nutritious foods to my diet. There were some mild side effects at first – nausea, bloating, gas, and belching – but they mostly went away after a week. Overall, I wish I had done this sooner

1.7

Patient Review

6/8/2012

Glucophage Xr for Type 2 Diabetes Mellitus

I felt nauseous and bloated when I first started taking this medication, but reducing the dosage helped. After a few days on a lower dose, I was able to increase it again and have been feeling better for the past two weeks.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about glucophage xr

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the difference between metformin and Glucophage XR?

"Metformin ER is a drug used to treat type 2 diabetes. It is the extended-release version of metformin and only needs to be taken once daily with food. The maximum total daily dose of metformin ER is 2000 mg. Metformin ER is only indicated for adults with type 2 diabetes."

Answered by AI

How quickly does Glucophage XR work?

"results are usually seen within 2 days of taking the medication, however timing varies depending on dosage. other diabetes medication work to increase insulin in the body, which can work faster to lower blood sugar levels."

Answered by AI

What is Glucophage XR used for?

"This medication is used to treat type 2 diabetes. By controlling high blood sugar levels, it helps to prevent damage to the kidneys, blindness, nerve problems, loss of limbs, and sexual function problems. Proper control of diabetes may also reduce your risk of having a heart attack or stroke."

Answered by AI

What are the side effects of Glucophage XR?

"Strong or unusual muscle pain, feeling cold, difficulty breathing, feeling dizzy or lightheaded, feeling very tired or weak, stomach pain, or vomiting, or a slow or irregular heart rate may be signs that something is wrong."

Answered by AI

Clinical Trials for Glucophage Xr

Image of Research Institute of the McGill University Health Centre Royal Victoria Hospital in Montreal, Canada.

Semaglutide for Type 1 Diabetes

18 - 65
All Sexes
Montreal, Canada

The goal of this 24 week double-blinded, randomized, parallel controlled clinical trial is to learn how semaglutide affects body composition in adults with type 1 diabetes and overweight/obesity. The main question to answer is: What effect does Semaglutide have on body composition in adults with type 1 diabetes and overweight/obesity compared to a placebo? Around 40 participants will: * Be randomly assigned to receive semaglutide or a placebo. * Self-administer the treatment drug once per week for 24 weeks. * Complete a series of tests, measurements and questionnaires throughout the study duration. * Attend a remote follow-up visit 4 weeks after the treatment is complete.

Phase 2 & 3
Recruiting

Research Institute of the McGill University Health Centre Royal Victoria Hospital

Melissa-Rosina Pasqua, MD, PhD

Image of University of Cincinnati Medical Center in Cincinnati, United States.

Continuous Glucose Monitoring for Type 2 Diabetes

18+
All Sexes
Cincinnati, OH

The TRANSITION-CGM trial will evaluate whether starting continuous glucose monitoring (CGM) before hospital discharge improves blood glucose control in adults with type 2 diabetes compared with usual care using finger-stick blood glucose checks. The study focuses on the transition from hospital to home, when patients may face changes in diabetes medications and challenges managing their blood glucose levels. This single-center, randomized controlled trial will enroll approximately 218 adults with type 2 diabetes, a hemoglobin A1c (HbA1c) 9% and above, and treatment with insulin and/or oral diabetes medications. Participants will be recruited during hospitalization and must be expected to return home after discharge. People already using a CGM will not be eligible. Participants will be randomly assigned in equal numbers to one of two groups. The CGM group will start using a continuous glucose monitor before discharge and receive device training and written instructions. The usual-care group will continue finger-stick blood glucose monitoring and receive standard discharge education. Both groups will receive assistance with outpatient diabetes follow-up. Diabetes medications will be managed by treating clinicians according to usual clinical practice. Participants will be followed for approximately 12 weeks after discharge, with an early follow-up encounter and a final assessment at 12 weeks. The primary outcome is HbA1c at 12 weeks, a blood test that reflects average blood glucose levels over approximately three months. Secondary outcomes include diabetes-related hospitalizations and episodes of low blood sugar. Additional exploratory measures include CGM use, follow-up attendance, patient-reported experiences, and time spent within the target glucose range when CGM data are available. The study will determine whether initiating CGM during hospitalization can improve glycemic control after discharge and provide preliminary evidence about its effects on diabetes-related hospitalizations and hypoglycemia.

Waitlist Available
Has No Placebo

University of Cincinnati Medical Center

Arunab H Mehta, MD, MEd

Have you considered Glucophage Xr clinical trials?

We made a collection of clinical trials featuring Glucophage Xr, we think they might fit your search criteria.
Go to Trials

Have you considered Glucophage Xr clinical trials?

We made a collection of clinical trials featuring Glucophage Xr, we think they might fit your search criteria.
Go to Trials
Image of Uni of Alabama at Birmingham in Birmingham, United States.

Zenagamtide for Obesity and Cardiovascular Risk

18+
All Sexes
Birmingham, AL

This clinical study is being conducted to evaluate the safety and effectiveness of zenagamtide in people with atherosclerotic cardiovascular disease (ASCVD) and excess body weight compared with placebo. The purpose of this clinical study is to find out if zenagamtide is safe and effective for treating people who have ASCVD and excess body weight. Participants will be randomly assigned by chance to receive either zenagamtide, the investigational treatment being tested, or a placebo, which contains no active medicine. Half of the participants will receive zenagamtide, and treatment assignment will be determined randomly. Zenagamtide is a new investigational medicine that is not yet available for prescription by doctors.

Phase 3
Waitlist Available

Uni of Alabama at Birmingham (+99 Sites)

Clinical Transparency (dept. 2834)

Novo Nordisk A/S

Image of Cardiovascular and Applied Physiology Laboratory in Tallahassee, United States.

Inspiratory Muscle Strength Training for Type 1 Diabetes

18 - 35
All Sexes
Tallahassee, FL

Adults with type 1 diabetes have elevated cardiovascular disease risk, and systolic blood pressure is a leading modifiable contributor to that risk. Aerobic exercise lowers blood pressure but poses time and glycemic-management barriers for people with type 1 diabetes. Inspiratory muscle strength training is a brief, home-based, device-based intervention that takes about five minutes per day and has lowered systolic blood pressure in other adult populations. This pilot trial will test whether eight weeks of daily high-resistance inspiratory muscle strength training lowers blood pressure and improves vascular function in adults with type 1 diabetes. Participants will be randomized 2:1 to high-resistance or very-low-resistance sham training using a POWERbreathe K3 device and will complete 30 training breaths per day at home for eight weeks. Outcomes are assessed before and after the training period.

Waitlist Available
New This Month

Cardiovascular and Applied Physiology Laboratory (+1 Sites)

Joseph C Watso

Image of St. Joseph's Health Care in London, Canada.

Semaglutide + Virtual Support for Obesity in Chronic Kidney Disease

18+
All Sexes
London, Canada

Obesity has a serious impact on people's health and quality of life. For those with advanced kidney disease (i.e. approaching the need for dialysis), obesity is especially problematic - obesity can not only lead to worsening kidney function and kidney failure, but it can also prevent patients from receiving a lifesaving kidney transplantation due to concerns about operation risks. Unfortunately, there is an urgent need but no rigorously proven treatments to help people with advanced kidney disease lose weight effectively and safely. The investigative team is a large team of doctors, nurses, dieticians, exercise specialists, social scientists, and patients with a lived experience, have spent three years advancing research to help people with advanced kidney disease achieve a healthier body weight. They have created a special weight loss program that combines individualized coaching on diet and save activity with a medication proven to help people with healthier kidneys lose weight (i.e. Ozempic). This research program is called PIVOT: Patient-centred Intervention with Virtual support for Obesity and kidney Transplant access. The investigators have started to test PIVOT in a small pilot study and early results show that there is potential to study the program on a much larger scale (i.e. across Canada). With funding from CIHR, the investigators aim to reach more Canadians with advanced kidney disease (including people of lower income, women, and people of different races) with an aim of helping them lose weight safely, feel better, obtain a kidney transplant, and staying healthier over the longer term.

Phase 4
Waitlist Available

St. Joseph's Health Care (+1 Sites)

Kristin Clemens, MD

Image of Stanford University in Palo Alto, United States.

Family Support Program for Type 1 Diabetes

Any Age
Female
Palo Alto, CA

The goal of this clinical trial is to learn if the "Insul-In This Together" family program works to improve outcomes for adolescents living with type 1 diabetes. It will also learn about how the program influences diabetes-related factors, including parenting. The main questions it aims to answer are: Does this program improve glycemic (blood glucose) outcomes? Does this program improve adolescent quality of life related to diabetes? Researchers will offer the program to all participating families, with one group receiving the program right after enrollment and another group receiving the program 6 months later. Adolescent and parent participants will: Attend 8 weekly 30-minute videoconference sessions with an interventionist Complete online surveys, share diabetes device data, and conduct at-home A1c tests 3-5 times over a 12-month period

Waitlist Available
Has No Placebo

Stanford University

Have you considered Glucophage Xr clinical trials?

We made a collection of clinical trials featuring Glucophage Xr, we think they might fit your search criteria.
Go to Trials